Amino Nitrogen Attached To Aryl Ring Or Ring System By An Acyclic Carbon Or Chain Patents (Class 564/336)
The aryl ring or ring system is bonded directly to another ring (Class 564/337)
Sulfur is part of the chain or is attached directly or indirectly to the acyclic carbon or chain by acyclic nonionic bonding with no amino nitrogen between the sulfur and the aryl ring or ring system (Class 564/340)
Carbonyl is part of the chain or is attached directly or indirectly to the acyclic carbon or chain by acyclic nonionic bonding with no amino nitrogen between the carbonyl and the aryl ring or ring system (Class 564/342)
Ether oxygen is part of the chain (Class 564/346)
Hydroxy, bonded directly to carbon, or ether oxygen attached directly or indirectly to the acyclic carbon or chain by acyclic nonionic bonding with no amino nitrogen between the hydroxy or ether oxygen and the aryl ring or ring system (h of -oh may be replaced by a substituted or unsubstituted ammonium ion or a group ia or iia light metal) (Class 564/355)
Halogen attached directly or indirectly to the acyclic carbon or chain by acyclic nonionic bonding with no amino nitrogen between the halogen and the aryl ring or ring system (Class 564/366)
The chain contains nitrogen between the aryl ring or ring system and amino nitrogen (Class 564/367)
Additional amino nitrogen attached directly or indirectly to the acyclic carbon or chain by acyclic nonionic bonding (Class 564/372)
Alpha aralkyl benzyl amines (Class 564/373)
The chain consists of two or more carbons which are unsubstituted or have acyclic hydrocarbyl substituents only (Class 564/374)
The aryl ring or ring system and amino nitrogen are bonded directly to the same acyclic carbon, which carbon additionally has only hydrogen or acyclic hydrocarbyl substituents bonded directly thereto (Class 564/384)
  • Production process for halogenated aromatic methylamine
    Patent number: 6960691
    Abstract: The invention intends to provide means for producing halogenated aromatic methylamine useful as an intermediate in the production of agrochemical or medical preparations, by an industrially advantageous method. The process according to the present invention for producing halogenated aromatic methylamine is characterized by comprising hydrogen-reducing a halogenated aromatic nitrile represented by formula (1): (wherein X represents a chlorine atom or a fluorine atom, m represents an integer of 1 to 5, n represents an integer of 1 to 5, m+n?6, and when n is 2 or more, each X may be the same or different) using a hydrogenating catalyst in the presence of an organic acid in a solvent to produce a halogenated aromatic methylamine represented by formula (2): (wherein X, m and n have the same meanings as defined above, and a represents an integer of 1 to m).
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: November 1, 2005
    Assignee: Showa Denko K.K.
    Inventors: Hideyuki Kondo, Yuseki Suyama, Kohei Morikawa
  • Process for preparing vanillylamine hydrochloride
    Patent number: 6958418
    Abstract: Process for preparing vanillylamine or one of the salts thereof by reacting vanillin with hydroxylamine or the salts thereof in the presence of an organic salt, which may optionally be produced in situ, wherein the reaction is carried out in an inorganic or organic acid as diluent, and subsequently hydrogenating the resulting vanillyloxime with hydrogen in the presence of a suitable catalyst and an organic and/or inorganic acid.
    Type: Grant
    Filed: June 9, 2005
    Date of Patent: October 25, 2005
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Oliver Meyer, Ingo Heddesheimer
  • Process for producing 2-phenylacetophenone derivatives and precursors therefor
    Patent number: 6956132
    Abstract: A process for producing 2-phenylacetophenone derivatives represented by the formula (I): (wherein X is an alkyl group or a haloalkyl group, and Y is a hydrogen atom, a halogen atom or an alkyl group which may be substituted), which comprises reacting a compound represented by the formula (II): (wherein X and Y are as defined above, and R is a hydrogen atom or an alkyl group) with an acid.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: October 18, 2005
    Assignee: Ishihara Sangyo Kaisha. Ltd.
    Inventors: Takeshi Ohshima, Shigeyuki Nishimura, Takayoshi Ando
  • Calcium receptor-active compounds
    Patent number: 6939895
    Abstract: A novel calcium receptor active compound having the formula is provided: Ar1—[CR1R2]p—X—[CR3R4]q—[CR5R6]—NR7—[CR8R9]—Ar2 wherein: Ar1 is selected from the group consisting of aryl, heteroaryl, bis(arylmethyl)amino, bis(heteroarylmethyl)amino and arylmethyl(heteroarylmethyl)amino; X is selected from the group consisting of oxygen, sulfur, sulfinyl, sulfonyl, carbonyl and amino; R1, R2, R3, R4, R5, R6, R7, R8 and R9 are, for example, hydrogen or alkyl; Ar2 is selected from the group consisting of aryl and heteroaryl; p is an integer of from 0 to 6, inclusive; and, q is an integer of from 0 to 14, inclusive.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: September 6, 2005
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Teruyuki Sakai, Atsuya Takami, Rika Nagao
  • Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
    Patent number: 6924393
    Abstract: The present invention relates to novel essentially pure venlafaxine and the process of preparation thereof. The present invention also relates to novel solvate forms of venlafaxine hydrochloride and the process of preparation thereof. Furthermore, the present invention provides a novel process for preparing venlafaxine hydrochloride from venlafaxine; the process comprises the steps of: i) preparing a mixture of venlafaxine with acetone; and ii) exposing the mixture in gaseous hydrochloric acid.
    Type: Grant
    Filed: October 7, 2004
    Date of Patent: August 2, 2005
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Ben-Zion Dolitzky, Judith Aronhime, Shlomit Wizel, Gannady A. Nisnevich
  • ?2-adrenergic receptor agonists
    Patent number: 6919482
    Abstract: Disclosed are multibinding compounds which are ?2-adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: July 19, 2005
    Assignee: Theravance, Inc.
    Inventors: Edmund J. Moran, Seok-Ki Choi
  • ?2-adrenergic receptor agonists
    Patent number: 6916961
    Abstract: Disclosed are multibinding compounds which are ?2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: July 12, 2005
    Assignee: Theravance, Inc.
    Inventors: Edmund J. Moran, Seok-Ki Choi
  • Primary intermediates for oxidative coloration of hair
    Patent number: 6916346
    Abstract: Primary intermediates for hair coloring compositions for oxidative dyeing of hair are compounds of the formula (1): wherein R is selected from C1 to C5 alkyl or hydroxyalkyl, a C3 to C6 cyclic ring containing hetero atoms selected from O, S and N atoms, and —CH2—Ar where Ar is an aromatic ring wherein the aromatic ring may be substituted with one or two hydroxy C1 to C3 alkoxy, or amino groups.
    Type: Grant
    Filed: May 5, 2004
    Date of Patent: July 12, 2005
    Assignee: The Procter & Gamble Company
    Inventors: Mu-Ill Lim, Yuh-Guo Pan
  • Polyamine analogs that activate antizyme frameshifting
    Patent number: 6914079
    Abstract: Novel polyamines, their synthesis and use in pharmacological, cosmetic or agricultural applications are provided. The polyamines induce antizyme production which in turn down regulates both the production of polyamines by ornithine decarboxylase (ODC) and the transport of polyamines by its corresponding polyamine transporter. These compounds will preferably enter the cell independent of the polyamine transporter. As drugs, these compounds are used to treat any disease associated with cellular proliferation including but not limited to cancer.
    Type: Grant
    Filed: September 23, 2002
    Date of Patent: July 5, 2005
    Assignee: MediQuest Therapeutics, Inc.
    Inventors: Mark R. Burns, Gerard F. Graminski
  • Methods of treating and preventing pain, anxiety, and incontinence using derivatives of (?)-venlafaxine
    Patent number: 6911479
    Abstract: Methods of preparing, and compositions comprising, derivatives of (?)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: June 28, 2005
    Assignee: Sepracor Inc.
    Inventors: Thomas P Jerussi, Chrisantha H Senanayake, Nandkumar N. Bhongle
  • Amino composition and process for producing the same
    Patent number: 6908982
    Abstract: An object of the present invention is to provide an amino composition which provides, when used as a curing agent for epoxy resin, a long pot life and an excellent appearance of a coating film to an epoxy resin composition without deteriorating the reactivity of the composition. The amino composition is obtained by addition reaction of diamine such as metaxylylenediamine and 1,3-bis(aminomethyl) cyclohexane and styrene, wherein the content of the diamine is less than 15% by weight based upon the total weight of the amino composition and the content of 1-addition product of having one phenethyl group is 50 to 100% by weight based upon the total weight of amino compound(s) obtained by the addition reaction.
    Type: Grant
    Filed: June 18, 2003
    Date of Patent: June 21, 2005
    Assignee: Mitsubishi Gas Chemical Company, Inc.
    Inventors: Tetsushi Ichikawa, Hisayuki Kuwahara, Masatoshi Echigo
  • Crystalline forms of venlafaxine hydrochloride
    Patent number: 6906087
    Abstract: Crystalline forms of Venlafaxine hydrochloride were found, referred to hereinafter as polymorphic Forms A, B and D. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: June 14, 2005
    Assignee: Ciba Specialty Chemicals Corpation
    Inventors: Paul Adriaan Van Der Schaaf, Claudia Marcolli, Martin Szelagiewicz, Beat Freiermuth
  • Fluorinated benzaldehydes
    Patent number: 6903239
    Abstract: The present invention relates to fluorinated benzaldehydes, to a process for preparing them and also to the use of the fluorinated benzaldehydes for preparing active ingredients, especially in medicaments and agrochemicals.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: June 7, 2005
    Assignee: Bayer Chemical Aktiengesellschaft
    Inventors: Karen Peilstöcker, Albrecht Marhold
  • Immunomodulation with novel pharmaceutical compositions
    Publication number: 20040235960
    Abstract: The synthesis and use of a novel class of tumor necrosis factor (TNF&agr;) inhibitors and immunomodulators are provided. These compounds have pharmacological applications as well as uses in assays relating to TNF&agr; and other involved cytokines. As pharmaceuticals, these compounds are used to treat inflammatory, infectious, autoimmune or other proliferative diseases and conditions related to the unwanted presence or activity of TNF&agr; and/or one or more other involved cytokines, alone or in combination with other agents.
    Type: Application
    Filed: May 23, 2003
    Publication date: November 25, 2004
    Inventors: Mark R. Burns, Maralee McVean, Kevin J. Kennedy, Arthur Yeung, Bruce H. Devens
  • Fullerene derivatives
    Publication number: 20040214218
    Abstract: A novel means for DNA compaction is provided.
    Type: Application
    Filed: May 17, 2004
    Publication date: October 28, 2004
    Applicants: Fujisawa Pharmaceutical Co., Ltd., Eiichi NAKAMURA
    Inventors: Eiichi Nakamura, Masaya Sawamura, Hiroyuki Isobe
  • Secondary amine mannich detergents
    Patent number: 6800103
    Abstract: New, highly effective detergent/dispersants for use in spark-ignition fuels comprising Mannich condensation products formed from (i) at least one substituted hydroxyaromatic compound having on the ring both (a) an aliphatic hydrocarbyl substituent derived from a polyolefin having a number average molecular weight in the range of about 500 to about 3000, and (b) a C1-4 (ii) at least one secondary amine; and (iii) at least one aldehyde are described. Carrier such as ploy(oxyalkylene) compounds further enhance the effectiveness of these Mannich condensation products in minimizing or reducing intake valve deposits and/or intake valve sticking.
    Type: Grant
    Filed: February 2, 2001
    Date of Patent: October 5, 2004
    Assignee: Ethyl Corporation
    Inventors: Dennis J. Malfer, Andrea T. Noble, William J. Colucci, Roger M. Sheets
  • Process of preparation of novel mannich bases from hydrogenated and distilled cashew nut shell liquid (CNSL) for use as additive in liquid hydrocarbon fuels
    Patent number: 6797021
    Abstract: A process for the preparation of Mannich condensation products from hydrogenated and distilled Cashew Nut Shell Liquid, amines and aldehydes which provides improved detergency in the gasoline.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: September 28, 2004
    Assignee: Indian Oil Corporation Limited
    Inventors: Suresh Kumar Puri, Anurag Ateet Gupta, M. Rajesh, Rameshwar Prasad, V. K. Sharma, M. Vanamamalai, Ved Singh, A. K. Misra, Niranjan Raghunath Raje, Som Prakash Srivastava, Akhilesh Bhatnagar
  • Novel use of sulfamic acids as resolving agent
    Publication number: 20040186298
    Abstract: The invention relates to the use of chiral sulfamic acids as resolving agents, the sulfamic acid having the formula (R1, R2?) N—SO3H, ?wherein: R1 and R2, ?being the same or different, represent a hydrogen atom or a C1-C30 linear, branched or cyclic (hetero)-aliphatic or (hetero)-aromatic group, provided that R1 ?and R2 are not both hydrogen and that at least one of the R1 and R2 groups is chiral. Further, methods for resolving enantiomeric mixtures are disclosed.
    Type: Application
    Filed: May 6, 2004
    Publication date: September 23, 2004
    Inventors: Alan Arthur Smith, Franciscus Wilhelmus Petrus Damen, George Johannes Theodorus Kuster
  • Substituted amino dicarboxylic acid derivatives
    Publication number: 20040176446
    Abstract: The invention relates to compounds of formula (I), to salts and stereoisomers thereof, to their production and to their use for producing medicaments used for treating cardiovascular diseases.
    Type: Application
    Filed: April 12, 2004
    Publication date: September 9, 2004
    Inventors: Cristina Alonso-Alija, Michael Harter, Michael Hahn, Josef Pernerstorfer, Stefan Weigand, Johannes-Peter Stasch, Frank Wunder
  • Novel compounds
    Publication number: 20040167227
    Abstract: Invented is paroxetine hydrochloride anhydrate in Form B and paroxetine hydrochloride anhydrate in Form D. Also invented are pharmacetucal formulations comprising these compounds and methods of using these compounds in therapy.
    Type: Application
    Filed: February 25, 2004
    Publication date: August 26, 2004
    Applicant: SmithKline Beecham Corporation
    Inventors: Neal Ward, Victor Witold Jacewicz
  • Substituted 2-aminoalkyl-1,4-diaminobenzene compounds and oxidation dye precursor compositions containing same
    Patent number: 6780998
    Abstract: The oxidation hair dye precursor composition contains from 0.005 to 20.0 percent by weight of one or more coupler compounds and from 0.005 to 20.0 percent by weight of one or more developer compounds. The one or more developer compounds include at least one substituted 2-aminoalkyl-1,4-diaminobenzene compound of the formula (I): New substituted 2-aminoalkyl-1,4-diaminobenzene compounds of formula (I) are described.
    Type: Grant
    Filed: April 17, 2002
    Date of Patent: August 24, 2004
    Assignee: Wella Aktiengesellschaft
    Inventors: Laurent Chassot, Hans-Juergen Braun
  • Primary intermediates for oxidative coloration of hair
    Patent number: 6774244
    Abstract: Primary intermediates for hair coloring compositions for oxidative dyeing of hair are compounds of the formula (1): wherein R is selected from C1 to C5 alkyl or hydroxyalkyl, a C3 to C6 cyclic ring containing hetero atoms selected from O, S and N atoms, and —CH2—Ar where Ar is an aromatic ring wherein the aromatic ring may be substituted with one or two hydroxy C1 to C3 alkoxy, or amino groups.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: August 10, 2004
    Assignee: The Procter & Gamble Company
    Inventors: Mu-Ill Lim, Yuh-Guo Pan
  • Substituted 1 and 2-naphthol mannich bases
    Publication number: 20040147570
    Abstract: The invention relates to substituted 1 and 2 naphthol Mannich bases, a method for the production thereof, medicaments containing said compounds and the use of said compounds in the production of medicaments.
    Type: Application
    Filed: January 15, 2004
    Publication date: July 29, 2004
    Applicant: GRUENENTHAL GMBH
    Inventors: Matthias Gerlach, Corinna Maul
  • Amines, uses thereof
    Publication number: 20040143009
    Abstract: The present invention relates to novel secondary or tertiary amines useful for smoothing wrinkles and fine lines, in particular expression wrinkles and fine lines.
    Type: Application
    Filed: November 6, 2003
    Publication date: July 22, 2004
    Applicant: L'OREAL
    Inventors: Maria Dalko, Lionel Breton, Christophe Boulle
  • Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and parkinson's disease
    Publication number: 20040127555
    Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A&bgr; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.
    Type: Application
    Filed: May 30, 2003
    Publication date: July 1, 2004
    Inventors: Alan D. Snow, Beth P. Nguyen, Gerardo M. Castillo, Virginia J. Sanders, Thomas P. Lake, Lesley Larsen, Rex T. Weavers, Stephen D. Lorimer, David S. Larsen, David L. Coffen, Charlotte Coffen
  • Intermediate and processes for its preparation and conversion into a pharmacologically-active agent
    Patent number: 6756502
    Abstract: Processes for the preparation of Venlafaxine (IX) via the novel epoxy-nitrile intermediate (I), which when subjected to hydrogenation forms compound (X), and may subsequently be reduced to yield the desired product (IX). The epoxy-nitrile intermediate (I) itself may be synthesized via various alternative reaction strategies, from a range of starting materials. E.g. 4-methoxy-benzaldehyde (VI), upon treatment with cyclohexyl magnesium bromide yields compound (V). This in turn may be oxidized to yield compound (III), which forms compound (II) on treatment with an (x-keto-halogenation agent. Cyanation of compound (II), then yields the desired epoxy nitrile intermediate (I), from which Venlafaxine (IX) may be synthesized.
    Type: Grant
    Filed: April 10, 2002
    Date of Patent: June 29, 2004
    Assignee: Alembic Limited
    Inventors: Dhiraj Mohansinh Rathod, Srinivasan Rengaraju, Milind Moreshwar Gharpure, Nishant Mahendra Patel, Mandar Manohar Deoahar
  • Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers
    Publication number: 20040116415
    Abstract: This invention relates to a method of treating disorders responsive to the blockade of sodium ion channels using novel aminoalkyl-substituted aryl compounds of Formula I: 1
    Type: Application
    Filed: July 31, 2003
    Publication date: June 17, 2004
    Applicant: Euro-Celtique S.A.
    Inventors: Qun Sun, Donald J. Kyle
  • Muscarinic receptor antagonists
    Publication number: 20040110229
    Abstract: Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modulator provided that at least one of said ligand is a muscarinic receptor antagonist. The multibinding compounds of this invention are useful in the treatment and prevention of diseases such as chronic obstructive pulmonary disease, chronic bronchitis, irritable bowel syndrome, urinary incontinence, and the like.
    Type: Application
    Filed: April 29, 2003
    Publication date: June 10, 2004
    Inventors: James Aggen, John H. Griffin, Mathai Mammen, Daniel Marquess, Edmund J. Moran, David Oare
  • Amine compounds, their production and use
    Publication number: 20040077867
    Abstract: A compound of the formula: 1
    Type: Application
    Filed: August 21, 2003
    Publication date: April 22, 2004
    Inventors: Kaneyoshi Kato, Jun Terauchi, Hiroaki Fukumoto, Mitsuru Kakihana
  • Sulfur-containing thyroxane derivatives and their use as hair growth promotors
    Patent number: 6723717
    Abstract: The present disclosure describes novel compounds of formula (A), wherein R1-R12, X and Y have the meanings given in the specification and compositions containing them which are particularly useful for treating hair loss in mammals, including arresting and/or reversing hair loss and promoting hair growth. The compounds described herein are cardiac-sparing.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: April 20, 2004
    Assignee: The University of Texas Southwestern Medical Center
    Inventors: Robert Scott Youngquist, John McMillan McIver
  • Preparation of 4-methyl-2,3,5,6-tetrafluorobenzyl alcohol
    Publication number: 20040063993
    Abstract: A process for the preparation of 4-methyl-2,3,5,6-tetrafluorobenzyl alcohol comprising hydrogenating 4-methyl-2,3,5,6-tetrafluorobenzonitrile to 4-methyl-2,3,5,6-tetrafluorobenzylamine and converting 4-methyl-2,3,5,6-tetrafluorobenzylamine to 4-methyl-2,3,5,6-tetrafluorobenzyl alcohol. The process optionally also comprises the further step of reacting 4-Methyl-2,3,5,6-tetrafluobenzyl alcohol with cis-Z-3-(2-chloro-1,1,1-trifluoro-2-propenyl)-2,2-dimethylcyclopropanecarbonyl chloride to the form tefluthrin. 4-Methyl-2,3,5,6-tetrafluorobenzylamine and salts thereof are also claimed.
    Type: Application
    Filed: April 25, 2003
    Publication date: April 1, 2004
    Inventors: Raymond Vincent Heavon Jones, Stephen Martin Brown
  • Polyamine analogs that activate antizyme framshifting
    Publication number: 20040058954
    Abstract: Novel polyamines, their synthesis and use in pharmacological, cosmetic or agricultural applications are provided. The polyamines induce antizyme production which in turn down regulates both the production of polyamines by ornithine decarboxylase (ODC) and the transport of polyamines by its corresponding polyamine transporter. These compounds will preferably enter the cell independent of the polyamine transporter. As drugs, these compounds are used to treat any disease associated with cellular proliferation including but not limited to cancer.
    Type: Application
    Filed: September 23, 2002
    Publication date: March 25, 2004
    Applicant: MediQuest Therapeutics, Inc.
    Inventors: Mark R. Burns, Gerard F. Graminski
  • 1,7, and 1,9-diarylpolymethine salts
    Publication number: 20040054178
    Abstract: The invention relates to 1,7-diarylpentamethine and 1,9-diarylheptamethine salts, in partricular heptacarbon or nonacarbon carboxonium salts, and streptocyanines.
    Type: Application
    Filed: June 6, 2003
    Publication date: March 18, 2004
    Inventors: Yves Madaule, Corrine Payrastre, Albert Izquierdo
  • Coupler for use in oxidative hair dyeing
    Patent number: 6703526
    Abstract: Couplers for hair coloring compositions for oxidative dyeing of hair are compounds of formula (1): wherein X is selected from of halogen and R5SO4 R3 is selected from C1 to C2 alkyl and hydroxyethyl; and R, R1, R2 and R5 are each independently selected from C1 to C22 alkyl or C1 to C22 mono or dihydroxyalkyl.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: March 9, 2004
    Assignee: The Procter & Gamble Company
    Inventors: Mu-Ill Lim, Yuh-Guo Pan, Margaret Popp
  • Cannabinoid receptor agonists
    Publication number: 20040044051
    Abstract: A compound of the formula 1
    Type: Application
    Filed: June 17, 2003
    Publication date: March 4, 2004
    Applicant: Schering Corporation
    Inventors: Joseph A. Kozlowski, Bandarpalle B. Shankar, Neng-Yang Shih, Ling Tong
  • Transfer hydrogenation process
    Patent number: 6696608
    Abstract: A catalytic transfer hydrogenation process is provided. The process can be employed to transfer hydrogenate N-substituted imines and iminium salts, which are preferably prochiral. The catalyst employed in the process is preferably a metal complex with one hydrocarbyl or cyclopentadienyl ligand and which is also coordinated to defined bidentate ligands. Preferred metals include rhodium, ruthenium and iridium. Preferred bidentate ligands are diamines and aminoalcohols, particularly those comprising chiral centres. The hydrogen donor is advantageously a mixture of triethylamine and formic acid. A process for the production of primary and secondary amines using the catalytic transfer hydrogenation of the N-substituted imines and iminium salts is also provided.
    Type: Grant
    Filed: February 14, 2002
    Date of Patent: February 24, 2004
    Assignee: Avecia Limited
    Inventors: Juliette Martin, Lynne Alison Campbell
  • Antitumor agents
    Publication number: 20040034202
    Abstract: The present invention provides compounds of general formula I or II: 1
    Type: Application
    Filed: April 14, 2003
    Publication date: February 19, 2004
    Applicant: The Regents of the University of California
    Inventors: Trevor C. McMorris, Michael J. Kelner
  • Methods for preparing O-desmethylvenlafaxine
    Patent number: 6689912
    Abstract: The present invention provides an efficient method of making O-desmethyl-venlafaxine.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: February 10, 2004
    Assignee: Wyeth
    Inventor: Beat T. Weber
  • Substituted 1,4-diaminobenzene compounds and oxidation dye precursor compositions containing same
    Patent number: 6685751
    Abstract: New substituted 2,5-diamino-1-aminomethylbenzene compounds of formula (I), or physiologically compatible water-soluble salts thereof, are described as well as methods for preparing them. In addition, oxidation dye precursor compositions for dyeing keratin fibers, especially human hair, which each contain from 0.005 to 20 percent by weight of at least one of the new substituted 2,5-diamino-1-aminomethylbenzene compounds of formula (I), or their physiologically compatible water-soluble salts, are described. Methods for dyeing hair with ready-to-apply dye mixtures made by mixing these oxidation dye precursor compositions with an oxidizing agent, such as hydrogen peroxide solution, are also described.
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: February 3, 2004
    Assignee: Wella Aktiengesellschaft
    Inventors: Laurent Chassot, Hans-Juergen Braun
  • Monoamine reuptake inhibitors for treatment of CNS disorders
    Patent number: 6677378
    Abstract: The present invention relates to compounds of the formula wherein R1 through R4, X, Y, m and n are defined as in the specification. Such compounds are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.
    Type: Grant
    Filed: April 30, 2001
    Date of Patent: January 13, 2004
    Assignee: Pfizer Inc.
    Inventors: Harry R. Howard, Jr., Christopher J. Schmidt, Thomas F. Seeger, Mark L. Elliott
  • Preparation of enantiomerically enriched amine-functionalized compounds
    Publication number: 20040006225
    Abstract: Process for removing a residual fragment of a chiral auxiliary from a diastereomeric compound with formula (2) 1
    Type: Application
    Filed: November 26, 2002
    Publication date: January 8, 2004
    Inventors: Marcelles Sluis Van Der, Quirinus Bernardus Broxterman, Ben Lange De
  • Alkoxybenzylamine
    Publication number: 20040006061
    Abstract: There are described alkoxybenzylamines corresponding to formula 1
    Type: Application
    Filed: October 2, 2002
    Publication date: January 8, 2004
    Inventors: Wolfgang Haap, Werner Holzl, Karin Petzold
  • Succinate salt of O-desmethyl-venlafaxine
    Patent number: 6673838
    Abstract: A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.
    Type: Grant
    Filed: February 11, 2002
    Date of Patent: January 6, 2004
    Assignee: Wyeth
    Inventors: Anthony F. Hadfield, Syed M. Shah, Michael W. Winkley, Karen W. Sutherland, James A. Provost, Aeri Park, Rex A. Shipplett, Brenton W. Russell, Beat T. Weber
  • Aryl aniline &bgr;2 adrenergic receptor agonists
    Patent number: 6670376
    Abstract: The invention provides novel &bgr;2 adrenergic receptor agonist compounds of formula (I): wherein R1-R13 and w have any of the values described in the specification. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with &bgr;2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: December 30, 2003
    Assignee: Theravance, Inc.
    Inventors: Edmund J. Moran, John R. Jacobsen, Michael R. Leadbetter, Matthew B. Nodwell, Sean G. Trapp, James Aggen, Timothy J. Church
  • Substituted aromatic policyclic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
    Publication number: 20030225088
    Abstract: The invention relates to substituted aromatic polycyclic tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases.
    Type: Application
    Filed: September 26, 2002
    Publication date: December 4, 2003
    Applicant: G.D. Searle & Co.
    Inventors: James A. Sikorski, Richard C. Durley, Mark A. Massa, Jane L. Wang, Deborah A. Mischke, Barry L. Parnas, Melvin L. Rueppel
  • Novel substituted diamine derivatives useful as motlin antagonists
    Publication number: 20030203906
    Abstract: The present invention relates to novel substituted diamine derivatives for the formula 1
    Type: Application
    Filed: November 8, 2002
    Publication date: October 30, 2003
    Inventors: Sigmong G. Johnson, Ralph A. Rivero
  • Triaromatic vitamin D analogues
    Publication number: 20030195259
    Abstract: The invention relates, as novel and useful industrial products, to triaromatic compounds, which are vitamin D analogues, of general formula (I): 1
    Type: Application
    Filed: December 10, 2002
    Publication date: October 16, 2003
    Inventors: Jean-Michel Bernardon, Thibaud Biadatti
  • HIV integrase inhibitors
    Publication number: 20030181490
    Abstract: The present invention relates to the inhibition of HIV integrase, and to the treatment of AIDS or ARC by administering compounds of the formula 1
    Type: Application
    Filed: September 25, 2002
    Publication date: September 25, 2003
    Inventors: Michael A. Walker, Timothy D. Johnson, Nicholas A. Meanwell, Jacque Banville
  • Second-order nonlinear optics material, the devices using same and methods of preparing
    Patent number: 6623665
    Abstract: The present invention relates to nonlinear optical (NLO) materials, compositions thereof and NLO devices using polymeric matrices supporting a second order NLO material defined by the formula ED—B—EW  (I) where ED is an electron donating moiety, B is a bridging moiety, and EW is the electron withdrawing moiety (terminal acceptor group) defined by formula II, where C1 is a carbon atom linked through a double bond to a cyclic or an acylic carbon atom in the bridging moiety, and A1, A2, A3 or A4are the same or different from one another, each of which is an electron withdrawing group such as CN, COR, COOR, COOH or CH═C(R)2 where R is a C1-6 alkyl.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: September 23, 2003
    Assignee: Lockheed Martin Corporation
    Inventor: Susan P. Ermer
  • Substituted dithiobisnitrobenzenes and their applications
    Publication number: 20030175848
    Abstract: The invention concerns substituted dithio-bis-nitrobenzenes (dithio-bis-nitrobenzylamines, dithio-bis-nitrobenzamides or dithio-bis-nitrophenacyls) and their uses as alternative substrates for NAD(P)H-dependent disulphide-reductase enzymes, such as trypanothion reductase and thioredoxine reductase and as a means for screening inhibitors of said enzymes. The invention also concerns an enzymatic test using said substrates and assay kits containing them. Said dithio-bis-nitrobenzenes correspond to general formula (I).
    Type: Application
    Filed: January 22, 2003
    Publication date: September 18, 2003
    Applicant: Institut Pasteur De Lille
    Inventors: Elisabeth Davioud-Charvet, Christian Sergheraert, Katja Becker-Brandenburg, Heiner Schirmer